Karyopharm Therapeutics | KPTI - Ordinary Share Capital


Karyopharm Therapeutics reported $22.54M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Abbott USD 1.74B 2.94M Mar/2026
Amgen USD 541M 1000K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
MacroGenics USD 63.56M 241K Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Takeda JPY 1.58B 460K Jun/2026
Tectonic Therapeutic USD 18.83M 92.19K Mar/2026
TG Therapeutics USD 153.08M 2.23M Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Xencor USD 74.33M 265K Jun/2026